$HEM declared the addition of an entirely closely-held subsidiar
Hemostemix recently declared the incorporation of PreCerv inc . (A totally closely-held subsidiary of Hemostemix). Hemostemix can grant PreCerv a world field of use licence for NCP-01 and its autologous somatic cell technology to treat central and peripheral systema nervosum diseases.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0172 USD
−1.89 M USD
0.00 USD
130.77 M
About HEMOSTEMIX INC
Sector
Industry
CEO
Thomas A. Smeenk
Website
Headquarters
Calgary
Founded
2006
FIGI
BBG00BNK7PL9
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen and Thomas A. Smeenk in 2006 and is headquartered in Calgary, Canada.
Hemostemix Inc. interest payment on convertible debenture
Hemostemix Inc. announced that it will pay interest of $84,804.40 by issuing 446,339 Common Shares, using the March 2, 2022 closing price of $0.19 per share, to the convertible debenture holder in satisfaction of interest due on the outstanding principal amount of $2,500,000 for the period from in
The recovery of lost intellectual data opens door to new opportu
As the court ruled in the favor of Hemostemix and all the intellectual property relating to ACP-01 was returned to Hemostemix, the management is independent to cultivate important business development strategies as well as it enables the extraction of phase 2 clinical trial data.
Hemostemix $HEM has an agreement with Aspire Health Science.
Hemostemix (TSXV: $HEM) primarily deals with developing and commercializing innovative blood-derived stem cell therapies. Is now entered into an agreement with Aspire and has agreed to settle the dispute of data stealth and intellectual property infringement regarding ACP-01.
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of HMTXF is 0.0694 USD — it has increased by 4.99% in the past 24 hours. Watch Hemostemix Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Hemostemix Inc stocks are traded under the ticker HMTXF.
HMTXF stock has risen by 4.99% compared to the previous week, the month change is a −18.40% fall, over the last year Hemostemix Inc has showed a 87.06% increase.
HMTXF reached its all-time high on Jan 7, 2016 with the price of 13.6000 USD, and its all-time low was 0.0240 USD and was reached on Jul 22, 2024. View more price dynamics on HMTXF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
HMTXF stock is 4.76% volatile and has beta coefficient of 0.36. Track Hemostemix Inc stock price on the chart and check out the list of the most volatile stocks — is Hemostemix Inc there?
Today Hemostemix Inc has the market capitalization of 9.97 M, it has increased by 0.92% over the last week.
Yes, you can track Hemostemix Inc financials in yearly and quarterly reports right on TradingView.
Hemostemix Inc is going to release the next earnings report on May 6, 2025. Keep track of upcoming events with our Earnings Calendar.
HMTXF net income for the last quarter is −232.47 K USD, while the quarter before that showed −379.48 K USD of net income which accounts for 38.74% change. Track more Hemostemix Inc financial stats to get the full picture.
No, HMTXF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, HMTXF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Hemostemix Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Hemostemix Inc technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Hemostemix Inc stock shows the sell signal. See more of Hemostemix Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.